(Q39634053)

13 September 2017

title

Liposomal SLA co-incorporated with PO CpG ODNs or PS CpG ODNs induce the same protection against the murine model of leishmaniasis (English)

1 reference

13 September 2017

1 reference

Vahid Heravi Shargh

1

1 reference

13 September 2017

Mahmoud Reza Jaafari

2

1 reference

13 September 2017

Ali Khamesipour

3

1 reference

13 September 2017

Iman Jaafari

4

1 reference

13 September 2017

Seyed Amir Jalali

5

1 reference

13 September 2017

Azam Abbasi

6

1 reference

13 September 2017

Ali Badiee

7

1 reference

13 September 2017

language of work or name

English

0 references

publication date

29 March 2012

1 reference

13 September 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

13 September 2017

volume

30

1 reference

13 September 2017

issue

26

1 reference

13 September 2017

page(s)

3957-3964

1 reference

Leishmaniasis vaccines: past, present and future

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Drug resistance in leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Vaccines against leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Vaccination against cutaneous leishmaniasis: current status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

First generation leishmaniasis vaccines: a review of field efficacy trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Pharmacokinetics of antisense oligonucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Phosphorothioate oligodeoxynucleotides: antisense or anti-protein?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Immunostimulation and anti-DNA antibody production by backbone modified CpG-DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Nucleic acids exert a sequence-independent cooperative effect on sequence-dependent activation of Toll-like receptor 9.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

The DNA sugar backbone 2' deoxyribose determines toll-like receptor 9 activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

CpG motif-independent activation of TLR9 upon endosomal translocation of "natural" phosphodiester DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Use of CpG oligodeoxynucleotides as immunoprotective agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Lipid-based formulations of antisense oligonucleotides for systemic delivery applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Use of CpG oligodeoxynucleotides as immune adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Efficient delivery of Antennapedia homeodomain fused to CTL epitope with liposomes into dendritic cells results in the activation of CD8+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

A review of adjuvants for Leishmania vaccine candidates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Intraperitoneal immunization with oligomannose-coated liposome-entrapped soluble leishmanial antigen induces antigen-specific T-helper type immune response in BALB/c mice through uptake by peritoneal macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Vaccination with the Leishmania major ribosomal proteins plus CpG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Cellular vaccination with bone marrow-derived dendritic cells pulsed with a peptide of Leishmania infantum KMP-11 and CpG oligonucleotides induces protection in a murine model of visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

A Toll-like receptor recognizes bacterial DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Immunostimulatory oligodeoxynucleotide isolated from genome wide screening of Mycobacterium bovis chromosomal DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

NF-kappaB-dependent regulation of tumor necrosis factor-alpha gene expression by CpG-oligodeoxynucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Enhancement of immunomodulatory activity by liposome-encapsulated natural phosphodiester bond CpG-DNA in a human B cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Improvement of in vivo stability of phosphodiester oligonucleotide using anionic liposomes in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Cationic liposomes enhance cellular/nuclear localization of 99mTc-antisense oligonucleotides in target tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

CpG motifs in bacterial DNA and their immune effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Immunostimulation of dendritic cells by cationic liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

The relationship of IL-4- and IFNγ-producing T cells studied by lineage ablation of IL-4-producing cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Analysis of cytokine mRNA levels in interleukin-4-transgenic mice by quantitative polymerase chain reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: priming for IL-12 and tumor necrosis factor alpha production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

IL-4 receptor expression on CD8+ T cells is required for the development of protective memory responses against liver stages of malaria parasites.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

The immunology of susceptibility and resistance to Leishmania major in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.040

10.1016/J.VACCINE.2012.03.040

7 January 2021

Identifiers

DOI

1 reference

13 September 2017

1 reference